ReviewCurrent rheumatology reports2020
Pregnancy Outcomes in Systemic Vasculitides.
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Pregnancy Outcome in a Patient With DADA2 Syndrome on Continued Adalimumab Therapy.International journal of rheumatic diseases · 2026Article
- Diagnostic delay and cardiovascular complications in Takayasu arteritis: a case-based review.Rheumatology international · 2025Review
- Reproductive Outcomes for Women With Vasculitis.The Journal of rheumatology · 2024Article
- Risk Assessment and Optimization for Pregnancy in Patients with Rheumatic Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- Successful pregnancies in a patient with Takayasu arteritis and antiphospholipid syndrome, maintained on infliximab corticosteroid-free regimen: case-based review.Rheumatology international · 2024Review
- Poor obstetric outcomes in women with takayasu arteritis: a retrospective cohort study.Rheumatology international · 2024Article
- Rare Autoinflammatory Neutrophilic Dermatoses in Pregnancy: Literature Review.American journal of clinical dermatology · 2024Review
- Exploring the understanding and experience of women with rheumatic diseases regarding fertility intention- a qualitative content analysis.BMC women's health · 2024Article
- Incidence, clinical features, management and outcomes of ANCA-associated vasculitis in pregnancy- a systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives.Archives of gynecology and obstetrics · 2023Review
- A comprehensive guide for managing the reproductive health of patients with vasculitis.Nature reviews. Rheumatology · 2022Review
- Article
- [New aspects of rare rheumatic diseases during pregnancy].Zeitschrift fur Rheumatologie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn recent years, improvements in the recognition of primary vasculitides and increased treatment options have led to greater survival rates and a better quality of life for patients. Therefore, pregnancy in women with vasculitis has become a more frequent consideration or event. Literature on pregnancy outcomes in this population has grown and allowed us, in this article, to review the effects of pregnancy on disease activity, as well as maternal and fetal outcomes for each type of vasculitides. RECENT
findingsSuccessful pregnancies in patients with vasculitides are possible, especially when conception is planned, and the disease is in remission. The risk of vasculitis flare is highly dependent on the type of vasculitis, but overall limited. The most frequent complication associated with large-vessel vasculitis (mainly Takayasu arteritis) is hypertension and preeclampsia. Preterm deliveries and intrauterine growth restriction occur more frequently with small- and medium-vessel vasculitis. Pregnancies in patients with vasculitis should be considered high risk and followed by a multidisciplinary team with expertise in the field. Flares should be managed as in the non-pregnant population, while avoiding medications with unknown safety in pregnancy or known teratogens. Although commonly prescribed for the prevention of preeclampsia, there is limited evidence supporting the use of low-dose aspirin for pregnant women with vasculitis. Prospective registries or studies are needed, to better assess the value of aspirin, the place and long-term impact of new biologics and, to identify predictors of pregnancy outcomes other than disease status at conception.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.